Video

Dr. Ornstein on antibody-drug conjugates for immunotherapy-refractory urothelial carcinoma

“The management of patients with advanced urothelial carcinoma whose cancer has progressed on immunotherapy presents a unique challenge,” says Moshe Ornstein, MD.

Video Player is loading.
Current Time 0:00
Duration 1:29
Loaded: 10.99%
Stream Type LIVE
Remaining Time 1:29
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Moshe Ornstein, MD, MA, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the emergence of antibody-drug conjugates as a treatment option for patients with immune checkpoint inhibitor–refractory advanced urothelial carcinoma.

    Related Content
    © 2025 MJH Life Sciences

    All rights reserved.